Autolus and BioNTech Enter into Strategic Alliance
On Thursday, February 8, Autolus and BioNtech announced (press release) a strategic CAR-T cell therapy collaboration to advance their pipelines and expand their late-stage programs. Below, Celltelligence provides insights on the partnership and how Autolus and BioNTech could benefit from it.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.